BioLife Solutions Inc (BLFS)
Return on equity (ROE)
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Net income | US$ in thousands | -66,427 | -139,805 | -8,908 | 1,983 | -1,657 |
Total stockholders’ equity | US$ in thousands | 337,663 | 364,188 | 478,047 | 204,429 | 43,321 |
ROE | -19.67% | -38.39% | -1.86% | 0.97% | -3.82% |
December 31, 2023 calculation
ROE = Net income ÷ Total stockholders’ equity
= $-66,427K ÷ $337,663K
= -19.67%
The return on equity (ROE) for BioLife Solutions Inc has fluctuated over the past five years. In 2023, the ROE was -19.67%, deteriorating significantly from the -1.86% in 2021 and -3.82% in 2019. The company experienced a steep decline in 2022 with a ROE of -38.39%. The positive ROE of 0.97% in 2020 was a brief improvement before the subsequent downward trend. Overall, BioLife Solutions Inc has struggled to generate satisfactory returns for its shareholders, with negative ROE figures in recent years indicating challenges in efficiently utilizing shareholder equity to generate profits.
Peer comparison
Dec 31, 2023
Company name
Symbol
ROE
BioLife Solutions Inc
BLFS
-19.67%
CONMED Corporation
CNMD
7.73%
LivaNova PLC
LIVN
1.37%
Masimo Corporation
MASI
5.97%
Medtronic PLC
MDT
7.32%